These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37782932)
1. In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA Belal H; Gandhi GY Ann Intern Med; 2023 Oct; 176(10):JC113. PubMed ID: 37782932 [TBL] [Abstract][Full Text] [Related]
2. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751 [TBL] [Abstract][Full Text] [Related]
3. In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA Belal H; Gandhi GY Ann Intern Med; 2023 Aug; 176(8):JC94. PubMed ID: 37523705 [TBL] [Abstract][Full Text] [Related]
4. In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA Griffin TP; Dinneen SF Ann Intern Med; 2021 Mar; 174(3):JC34. PubMed ID: 33646841 [TBL] [Abstract][Full Text] [Related]
5. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252 [TBL] [Abstract][Full Text] [Related]
6. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O; N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066 [TBL] [Abstract][Full Text] [Related]
7. In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA Belal H; Gandhi GY Ann Intern Med; 2023 Oct; 176(10):JC112. PubMed ID: 37782923 [TBL] [Abstract][Full Text] [Related]
8. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Bajaj HS; Ásbjörnsdóttir B; Carstensen L; Laugesen C; Mathieu C; Philis-Tsimikas A; Battelino T Diabetes Care; 2024 Apr; 47(4):729-738. PubMed ID: 38380954 [TBL] [Abstract][Full Text] [Related]
10. Once-Weekly Insulin Icodec Ribeiro E Silva R; de Miranda Gauza M; Guisso MES; da Silva JON; Kohara SK Arch Endocrinol Metab; 2023 May; 67(5):e000614. PubMed ID: 37249450 [TBL] [Abstract][Full Text] [Related]